Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Submitted by
admin
on November 5, 2011 - 2:49pm
Source:
Yahoo/PR NewsWire
News Tags:
Savient
Krystexxa
gout
Headline:
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Do Not Allow Advertisers to Use My Personal information
